Ann Intern Med:白大衣高血压也需要治疗?Meta分析称,未治疗者心脏病死亡风险增倍

2019-06-16 朱柳媛 中国循环杂志

近日,《内科学年鉴》杂志发表的一项入选27项研究的Meta分析表明,白大衣高血压患者如未接受治疗,不仅比血压正常者容易发生心脏病,而且死于心脏病的风险增加了一倍。

近日,《内科学年鉴》杂志发表的一项入选27项研究的Meta分析表明,白大衣高血压患者如未接受治疗,不仅比血压正常者容易发生心脏病,而且死于心脏病的风险增加了一倍。

但是,研究者发现,白大衣高血压患者如服用降压药物,发生心脏病或因心血管病死亡的风险与血压正常者相似。

所谓的“白大衣高血压”,是指患者在医疗环境中测量的血压高于正常水平,而离开后血压又正常。数据显示,大约两成成年人存在白大衣高血压。

既往认为,白大衣高血压与患者在医疗环境下紧张有关。

但近年来,越来越多的研究表明,白大衣高血压实际上是未来可能出现心脏病的一种征象。

研究者指出,需要重视白大衣高血压这一特殊情况。

他们认为,没有用降压药的单纯白大衣高血压患者需要密切监测血压,看看是否会转变为持续性的高血压,或者在家中和医生诊室是否都会出现血压升高。

该研究结果说明,需要加强诊室外血压监测。作者强调,“在高血压诊治过程中,诊室外的血压监测非常关键。”

研究者还建议,没有接受降压治疗的白大衣高血压患者要积极进行生活方式调节,包括戒烟、限制饮酒、改善饮食结构、加强运动。

当然,他们也提到,如果白大衣高血压患者已应用降压药物,临床医生则要注意不过度治疗。

该Meta分析纳入的27项研究共包含25 786例白大衣高血压患者以及38 487例血压正常者,这些研究平均随访3~19年。

分析结果显示,与血压正常人群相比,未接受降压治疗的白大衣高血压患者发生心血管事件、全因死亡和心血管死亡的风险分别增加36%、33%和109%。

心血管事件包括脑卒中的部分研究中,未治疗的白大衣高血压患者发生心血管事件、全因死亡和心血管死亡的风险有所降低,分别增加12%、11%和4%。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032446, encodeId=aff9203244690, content=<a href='/topic/show?id=eb245160e79' target=_blank style='color:#2F92EE;'>#心脏病死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51607, encryptionId=eb245160e79, topicName=心脏病死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Sep 15 00:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896503, encodeId=4544189650387, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 01 23:38:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706472, encodeId=0b8a1e0647251, content=<a href='/topic/show?id=b91fe1673b8' target=_blank style='color:#2F92EE;'>#白大衣高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71673, encryptionId=b91fe1673b8, topicName=白大衣高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d0231270259, createdName=yanjie6253_56072852, createdTime=Mon Jan 06 17:38:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888022, encodeId=99521888022ab, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 19 00:38:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255875, encodeId=bf2712558e5ff, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609826, encodeId=7c1a1609826bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032446, encodeId=aff9203244690, content=<a href='/topic/show?id=eb245160e79' target=_blank style='color:#2F92EE;'>#心脏病死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51607, encryptionId=eb245160e79, topicName=心脏病死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Sep 15 00:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896503, encodeId=4544189650387, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 01 23:38:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706472, encodeId=0b8a1e0647251, content=<a href='/topic/show?id=b91fe1673b8' target=_blank style='color:#2F92EE;'>#白大衣高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71673, encryptionId=b91fe1673b8, topicName=白大衣高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d0231270259, createdName=yanjie6253_56072852, createdTime=Mon Jan 06 17:38:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888022, encodeId=99521888022ab, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 19 00:38:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255875, encodeId=bf2712558e5ff, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609826, encodeId=7c1a1609826bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
    2019-08-01 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032446, encodeId=aff9203244690, content=<a href='/topic/show?id=eb245160e79' target=_blank style='color:#2F92EE;'>#心脏病死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51607, encryptionId=eb245160e79, topicName=心脏病死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Sep 15 00:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896503, encodeId=4544189650387, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 01 23:38:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706472, encodeId=0b8a1e0647251, content=<a href='/topic/show?id=b91fe1673b8' target=_blank style='color:#2F92EE;'>#白大衣高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71673, encryptionId=b91fe1673b8, topicName=白大衣高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d0231270259, createdName=yanjie6253_56072852, createdTime=Mon Jan 06 17:38:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888022, encodeId=99521888022ab, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 19 00:38:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255875, encodeId=bf2712558e5ff, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609826, encodeId=7c1a1609826bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2032446, encodeId=aff9203244690, content=<a href='/topic/show?id=eb245160e79' target=_blank style='color:#2F92EE;'>#心脏病死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51607, encryptionId=eb245160e79, topicName=心脏病死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Sep 15 00:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896503, encodeId=4544189650387, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 01 23:38:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706472, encodeId=0b8a1e0647251, content=<a href='/topic/show?id=b91fe1673b8' target=_blank style='color:#2F92EE;'>#白大衣高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71673, encryptionId=b91fe1673b8, topicName=白大衣高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d0231270259, createdName=yanjie6253_56072852, createdTime=Mon Jan 06 17:38:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888022, encodeId=99521888022ab, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 19 00:38:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255875, encodeId=bf2712558e5ff, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609826, encodeId=7c1a1609826bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
    2019-07-19 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=2032446, encodeId=aff9203244690, content=<a href='/topic/show?id=eb245160e79' target=_blank style='color:#2F92EE;'>#心脏病死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51607, encryptionId=eb245160e79, topicName=心脏病死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Sep 15 00:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896503, encodeId=4544189650387, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 01 23:38:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706472, encodeId=0b8a1e0647251, content=<a href='/topic/show?id=b91fe1673b8' target=_blank style='color:#2F92EE;'>#白大衣高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71673, encryptionId=b91fe1673b8, topicName=白大衣高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d0231270259, createdName=yanjie6253_56072852, createdTime=Mon Jan 06 17:38:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888022, encodeId=99521888022ab, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 19 00:38:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255875, encodeId=bf2712558e5ff, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609826, encodeId=7c1a1609826bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2032446, encodeId=aff9203244690, content=<a href='/topic/show?id=eb245160e79' target=_blank style='color:#2F92EE;'>#心脏病死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51607, encryptionId=eb245160e79, topicName=心脏病死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Sep 15 00:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896503, encodeId=4544189650387, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Aug 01 23:38:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706472, encodeId=0b8a1e0647251, content=<a href='/topic/show?id=b91fe1673b8' target=_blank style='color:#2F92EE;'>#白大衣高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71673, encryptionId=b91fe1673b8, topicName=白大衣高血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d0231270259, createdName=yanjie6253_56072852, createdTime=Mon Jan 06 17:38:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888022, encodeId=99521888022ab, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 19 00:38:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255875, encodeId=bf2712558e5ff, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609826, encodeId=7c1a1609826bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 18 07:38:00 CST 2019, time=2019-06-18, status=1, ipAttribution=)]
    2019-06-18 一叶知秋

相关资讯

JACC:白大衣高血压与心血管风险之间究竟有着怎样的关联?

白大衣高血压(WCH)及白大衣效应(WCE)在心血管疾病(CVD)风险的发展过程中的作用仍然很难理解。来自美国的研究人员使用了来自基于群体的11项队列IDACO(关于心血管结果的动态血压监测的国际数据库)研究的数据,该研究比较了653例WCH患者和653名健康对照者常规血压测量的日间动态血压监测数据。欧洲高血压指南被用于评估5阶段风险。低风险被定义为0至2个危险因素,高风险被定义为≥3至5个危险因

PLoS Med:Meta分析家庭血压监测有助于风险分层

根据一项最新的Meta分析,对于在一些常规环境(例如医生办公室)中看似血压正常的人,家庭血压监测可以极大地提高其风险分层。对于那些血压水平处于理想、正常、正常高值水平的人以及轻度高血压患者来说,家庭血压监测有助于识别心血管、心脏和脑血管事件,改善一级预防。该研究2014年1月21日发表于PLoS Medicine杂志。 Kei Asayama博士(比利时Leuven大学)和同事们在论文中写道

Hypertension:极高龄患者治疗白大衣高血压有益

  英国学者的一项研究表明,在极高龄人群中对白大衣性高血压实施降压治疗可能产生益处。论文于2012年11月19日在线发表于《高血压》(Hypertension)。   双盲随机HYVET试验在80岁以上高血压患者中对缓释吲哒帕胺联合培哚普利与匹配安慰剂进行了比较。此项研究为HYVET试验的子项目,并在受试者中测定了动态血压(ABP)。基线时112例患者测定了ABP,平均随访13个月后186例患者